Reuters
Published Jan 07, 2022 18:44
Updated Jan 07, 2022 19:55
LONDON (Reuters) -Booster jabs are still providing high levels of protection for older people against severe disease from the Omicron coronavirus variant and there is no need for now for people to have a fourth shot, British health officials said on Friday.
Around three months after receiving a third jab, protection against hospitalisation among those aged 65 and over remained at about 90%, the UK Health Security Agency said.
"The data is highly encouraging and emphasises the value of a booster jab," Wei Shen Lim, chair for COVID-19 immunisation on the government's Joint Committee on Vaccination and Immunisation, said in a statement.
By comparison, with only two vaccine doses, protection against severe disease for the over-65s dropped to around 70% after three months and to 50% after six months, the UKHSA said.
"The current data show the booster dose is continuing to provide high levels of protection against severe disease, even for the most vulnerable older age groups," Lim said.
"For this reason, the committee has concluded there is no immediate need to introduce a second booster dose, though this will continue to be reviewed."
Protection against mild symptomatic infection was more short-lived than against severe disease and dropped to around 30% after about three months, the UKHSA said.
Israel is now administering fourth doses to people over 60 and health workers, as well as immunocompromised patients, after finding they boost antibodies five-fold within a week.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.